Elevance Health, Inc. (ELV): who owns it and who trades it
As of Nov 16, 2026, ELV insiders reported 19 open-market sales worth $7M and 4 purchases worth $2.2M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mark Kaye (CFO), with $4.7M. 10 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Elevance Health
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, ELV insiders reported $2.2M of open-market purchases and $7M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Ratnakar Lavu | Vice president | Sale | 1,300 | $440.00 | $572K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 400 | $434.00 | $174K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 321 | $435.25 | $140K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 1,660 | $436.20 | $724K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 560 | $437.07 | $245K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 240 | $438.22 | $105K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 1,160 | $439.25 | $510K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 1,720 | $440.44 | $758K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 2,343 | $441.34 | $1M | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 480 | $442.61 | $212K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 440 | $443.81 | $195K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 160 | $444.85 | $71.2K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 827 | $446.05 | $369K | Form 4 |
| Oct 22, 2026 | Mark Kaye | CFO | Sale | 273 | $447.19 | $122K | Form 4 |
| Jul 17, 2026 | Ramiro G Peru | Director | Purchase | 1,000 | $366.05 | $366K | Form 4 |
| Jul 17, 2026 | Gail Boudreaux | CEO | Purchase | 680 | $366.41 | $249K | Form 4 |
| Jul 17, 2026 | Gail Boudreaux | CEO | Purchase | 2,045 | $368.25 | $753K | Form 4 |
| Jun 12, 2026 | Ronald W Penczek | CAO & Controller | Sale | 369 | $403.16 | $149K | Form 4 |
| Jun 11, 2026 | Robert L Dixon JR | Director | Sale | 151 | $401.77 | $60.7K | Form 4 |
| May 19, 2026 | Ronald W Penczek | CAO & Controller | Sale | 1,531 | $403.13 | $617K | Form 4 |
| Mar 12, 2026 | Amy W Schulman | Director | Sale | 26 | $287.50 | $7.5K | Form 4 |
| Mar 6, 2026 | Charles Morgan Kendrick JR | Vice president | Sale | 3,196 | $284.92 | $911K | Form 4 |
| Mar 5, 2026 | Steven H Collis | Director | Purchase | 3,000 | $289.84 | $870K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark Kaye | EVP & CFO | – | $4.7M | Oct 22, 2026 |
| Gail Boudreaux | President and CEO, Director | $1M | – | Jul 17, 2026 |
| Charles Morgan Kendrick JR | EVP & President, Commercial | – | $911K | Mar 6, 2026 |
| Steven H Collis | Director | $870K | – | Mar 5, 2026 |
| Ronald W Penczek | CAO & Controller | – | $766K | Jun 12, 2026 |
| Ratnakar Lavu | EVP & Chief Digital Info Ofr | – | $572K | Nov 5, 2026 |
| Ramiro G Peru | Director | $366K | – | Jul 17, 2026 |
| Robert L Dixon JR | Director | – | $60.7K | Jun 11, 2026 |
| Amy W Schulman | Director | – | $7.5K | Mar 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ELV short interest
Low short interest. 2.1% of ELV shares are sold short: about 1 share in 48. Over the last 12 reports the number of shares short went down 26%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.54M ELV shares were sold short, 2.1% of the shares outstanding, down 11.5% from the report before. At the average daily volume of 1.39M shares, buying them all back would take about 3.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.54M | 2.10% | -12% | 1.39M | 3.3 |
| Oct 15, 2026 | 5.14M | 2.38% | +6% | 1.29M | 4.0 |
| Sep 30, 2026 | 4.85M | 2.24% | -9% | 1.24M | 3.9 |
| Sep 15, 2026 | 5.34M | 2.46% | -3% | 1.27M | 4.2 |
| Aug 31, 2026 | 5.49M | 2.53% | +1% | 836,685 | 6.6 |
| Aug 14, 2026 | 5.41M | 2.49% | -3% | 952,831 | 5.7 |
| Jul 31, 2026 | 5.59M | 2.58% | -7% | 1.42M | 3.9 |
| Jul 15, 2026 | 6.03M | 2.78% | +0% | 1.71M | 3.5 |
| Jun 30, 2026 | 6.01M | 2.77% | -4% | 1.84M | 3.3 |
| Jun 15, 2026 | 6.28M | 2.89% | -5% | 1.79M | 3.5 |
| May 29, 2026 | 6.60M | 3.04% | +8% | 1.52M | 4.3 |
| May 15, 2026 | 6.10M | 2.81% | +18% | 1.66M | 3.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded ELV
Since Nov 17, 2024, 8 members of Congress reported 6 purchases and 9 sales of ELV. The latest was a purchase by Alan Armstrong on Mar 27, 2026, reported Jul 21, 2026.
Purchases 6Sales 9
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Mar 27, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
| Aug 13, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Sep 12, 2025 | Report |
| Aug 5, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | Sep 12, 2025 | Report |
| Jul 10, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 24, 2025 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| May 30, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Sale | $1K–$15K | Self | Jun 6, 2025 | Report |
| May 15, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $15K–$50K | Self | May 31, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | Jun 22, 2025 | Report |
| Apr 29, 2025 | Gilbert Ray Cisneros, Jr. (D-CA) | Purchase | $1K–$15K | Self | May 6, 2025 | Report |
| Apr 11, 2025 | Dan Newhouse (R-WA) | Partial sale | $1K–$15K | Spouse | May 16, 2025 | Report |
| Mar 10, 2025 | Jared Moskowitz (D-FL) | Sale | $1K–$15K | Child | Apr 8, 2025 | Report |
| Mar 10, 2025 | Jared Moskowitz (D-FL) | Sale | $1K–$15K | Self | Apr 8, 2025 | Report |
| Feb 24, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | Mar 9, 2025 | Report |
| Jan 13, 2025 | Val T. Hoyle (D-OR) | Sale | $1K–$15K | Spouse | Sep 12, 2025 | Report |
| Jan 13, 2025 | Robert P. Bresnahan, Jr. (R-PA) | Sale | $1K–$15K | Joint | Feb 13, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Elevance Health company events
Elevance Health filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026AnnouncementShared information with investors. Filing
- Oct 21, 2026ResultsReleased financial results. Filing
- Sep 10, 2026AnnouncementShared information with investors. Filing
- Jul 15, 2026ResultsReleased financial results. Filing
- Jun 10, 2026AnnouncementShared information with investors. Filing
- May 13, 2026VoteReported shareholder vote results. Filing
- Apr 22, 2026ResultsReleased financial results. Filing
- Mar 10, 2026AnnouncementShared information with investors. Filing
- Mar 2, 2026AnnouncementElevance Health, Inc. was notified by the Centers for Medicare & Medicaid Services of its intent to impose intermediate sanctions suspending enrollment of Medicare beneficiaries into the Company’s Medicare Advantage-Prescription Drug plans and suspending certain communication activities to Medicare… Filing
- Feb 26, 2026LeadershipElevance Health, Inc. announced certain management changes. Filing
- Jan 28, 2026ResultsReleased financial results. Filing
- Dec 10, 2025LeadershipThe Board of Directors of Elevance Health, Inc. elected Amy W. Schulman to serve as an independent director effective January 12, 2026, with a term expiring at the Company’s 2028 annual meeting of shareholders. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Elevance Health financials
Famous investors that hold ELV
10 of the 50 well-known investors we track reported holding ELV in their latest 13F filing. The largest position is Bill Nygren's, worth $1.9B.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Bill Nygren · Harris Associates (Oakmark) | Q3 2026 | 4.78M | $1.9B | 2.4% | -3% |
| Jeremy Grantham · GMO | Q3 2026 | 1.68M | $653M | 1.4% | -1% |
| Seth Klarman · Baupost Group | Q3 2026 | 1.28M | $496M | 9.8% | No change |
| Glenn Greenberg · Brave Warrior Advisors | Q3 2026 | 579,472 | $225M | 5.2% | -41% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 388,335 | $151M | 0.1% | -57% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 322,613 | $125M | 0.2% | +60% |
| Richard Pzena · Pzena Investment Management | Q3 2026 | 233,128 | $90.6M | 0.3% | +4% |
| Israel Englander · Millennium Management | Q3 2026 | 3,926 | $1.5M | 0.0% | -99% |
| Lee Ainslie · Maverick Capital | Q3 2026 | 3,465 | $1.3M | 0.0% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 1,660 | $646K | 0.0% | +3% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Elevance Health, Inc. (ELV) stock
Are ELV insiders buying or selling?
In the last 12 months, ELV insiders reported 4 open-market purchases worth $2.2M and 19 sales worth $7M. The latest trade was on Nov 5, 2026. See every trade.
What is the short interest in ELV?
As of Oct 30, 2026, 4.54M ELV shares were sold short, 2.1% of the shares outstanding, down 11.5% from the report before. At the average daily volume of 1.39M shares, buying them all back would take about 3.3 trading days (days to cover). See the history.
Have members of Congress traded ELV?
Yes. 8 members of Congress reported 6 purchases and 9 sales of ELV since Nov 17, 2024. The latest was reported on Jul 21, 2026. See the trades.
Which famous investors hold ELV?
10 of the 50 well-known investors we track reported ELV in their latest 13F filing, including Bill Nygren, Jeremy Grantham, Seth Klarman. The largest position is worth $1.9B. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.